Cancer Therapy AdvisorManagement of Node-Positive, High-Risk HR+/HER2– Early Breast Cancer in Adults

HR+/HER2- breast cancer accounts for roughly two-thirds of newly diagnosed US cases, with node-positive, high-risk patients facing up to 30% recurrence risk at 5 years despite optimal endocrine therapy. This case challenge presents a postmenopausal patient with stage IIB disease, grade 3 histology, and a 21-gene recurrence score of 33, illustrating contemporary adjuvant treatment decision-making.

Clinical Considerations

• monarchE 5-year data show abemaciclib plus endocrine therapy prevented one recurrence per 13 patients treated, with benefit deepening beyond the 2-year treatment window, predominantly reducing incurable metastatic recurrences
• Ki-67 threshold of 20% is no longer required for adjuvant abemaciclib eligibility; FDA removed it as a mandatory criterion, as benefit was demonstrated regardless of Ki-67 status
• Dose reductions occurred in 43% of monarchE patients without compromising efficacy, making modification a primary adherence tool rather than a treatment failure signal
• High-risk eligibility criteria include 4 or more positive nodes, or 1-3 positive nodes with grade 3 histology, tumor size 5 cm or larger, or Ki-67 at or above 20%

Practice Applications

• Assess high-risk eligibility at diagnosis using monarchE criteria: nodal burden, tumor size, grade, and Ki-67
• Consider abemaciclib plus endocrine therapy for node-positive patients meeting high-risk criteria before defaulting to endocrine therapy alone
• Counsel patients on early-onset diarrhea as the most common adverse event, and initiate antidiarrheal prophylaxis proactively
• Monitor for venous thromboembolism, grade 3 or higher neutropenia, and interstitial lung disease throughout the 2-year treatment course
• Evaluate endocrine therapy partner selection — tamoxifen vs aromatase inhibitor — to optimize tolerability and treatment completion

More in Breast Cancer